Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 3

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(5)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07571486Phase 1Not Yet Recruiting

Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis.

Role: collaborator

NCT05293197Phase 1Recruiting

Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

Role: collaborator

NCT05902169Phase 3Recruiting

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Role: lead

NCT04528680Phase 1Active Not Recruiting

Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

Role: collaborator

NCT05864534Phase 2Recruiting

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Role: collaborator

NCT03744026Phase 1Completed

Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9

Role: lead

NCT03119961Phase 1Completed

Blood Brain Barrier Opening in Alzheimer' Disease

Role: collaborator

All 7 trials loaded